Cure8 trial brief
This trial tests whether pomegranate juice can lower fecal calprotectin, a commonly used marker of intestinal inflammation, in people with IBD in remission. If effective, such a dietary approach could be of interest to patients and clinicians monitoring disease activity.
Adults with Crohn’s disease or ulcerative colitis in remission; clinicians monitoring fecal calprotectin; researchers of dietary interventions and biomarkers in IBD.
This is a completed interventional trial testing whether regular consumption of 100% pomegranate juice (125 mL twice daily for 12 weeks) reduces fecal calprotectin in adults with IBD who are in clinical remission.
The study measured fecal calprotectin as the primary outcome and assessed systemic and mucosal inflammatory markers plus ellagitannin-derived metabolites in blood and urine. Participants included adults with ulcerative colitis or Crohn’s disease in clinical remission, on stable medical therapy.
A placebo beverage (water with sugar and citric acid) was used for comparison. The planned enrollment was 18 and the study was conducted in Bologna, Italy. The full study protocol is published in Trials and the ClinicalTrials.gov registry lists the study as completed.
If you have IBD and are curious about dietary supplements or functional foods, this trial explores a specific dietary intervention (pomegranate juice) and uses fecal calprotectin as an objective marker of intestinal inflammation. It does not provide clinical recommendations or results in this registry entry.
Registry entry describes study design and outcomes (primary: change in fecal calprotectin at 12 weeks) but does not include the trial’s results. The planned enrollment was small (18); check the peer-reviewed publication for results and detailed analysis.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dietary strategies that reduce inflammation and oxidative stress could complement medical care for people with IBD by potentially lowering biomarkers linked to disease activity.
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
